A tenfold difference in relative risk—one that could translate into practical clinical benefit.
Across three centuries and ten generations, a single genetic mutation carried by early French settlers has quietly shaped the cancer landscape of Quebec — a reminder that history lives not only in culture and language, but in the very architecture of our cells. Researchers at McGill University have now identified this 'jumping gene' variant as a tenfold amplifier of pancreatic cancer risk in French-Canadian populations, one that older technologies could not see but newer sequencing methods can finally name. The discovery opens a door long closed: the possibility of finding those at risk before the disease finds them.
- A mutation born in the 1600s has been silently multiplying through French-Canadian bloodlines, appearing ten times more often in pancreatic cancer patients than in the general population.
- For decades, standard genetic tests were blind to this variant, leaving carriers unaware of a significantly elevated risk for both pancreatic and breast cancer.
- New sequencing technologies have finally made the mutation visible, transforming an invisible hereditary threat into something clinicians can now test for and act upon.
- McGill researchers are calling for targeted genetic panels built around founder mutations specific to populations like Quebec's French-Canadians, enabling earlier and more precise risk identification.
- Anyone who underwent genetic screening five to ten years ago may be carrying this variant without knowing it — and could benefit from re-evaluation through updated genetic counseling.
A McGill University research team has traced an unusually high rate of pancreatic cancer in Quebec's French-Canadian population to a single mutation that arrived with European settlers roughly 300 years ago. Published in the Journal of Medical Genetics, the discovery centers on a 'jumping gene' — a segment of DNA that copies and reinserts itself into the genome. When it lands within the ATM gene, it cripples the cell's ability to repair damaged DNA, substantially raising cancer risk across generations.
The concentration of this mutation in Quebec reflects what geneticists call the founder effect: because the original French settlers were few in number, rare variants that were uncommon in broader European populations became disproportionately prevalent among their descendants. The numbers are striking — the mutation appears in roughly 2% of French-Canadian pancreatic cancer patients, compared to just 0.2% of unaffected individuals, a tenfold difference. It has also been found at elevated rates in French-Canadian women with breast cancer.
For decades, the mutation was undetectable by standard genetic tests. Newer sequencing technologies have changed that, and researchers now see a clear clinical path forward. Rather than broad panels testing hundreds of variants, targeted screens focused on key founder mutations could identify high-risk individuals far earlier. Crucially, those who were tested five to ten years ago may have received incomplete results — and could benefit from re-evaluation as the science has meaningfully advanced.
A team of researchers at McGill University has traced the roots of an unusually high rate of pancreatic cancer in Quebec's French-Canadian population back three centuries, to a single genetic mutation that arrived with early European settlers and has been quietly amplifying ever since.
The discovery, published in the Journal of Medical Genetics, centers on what geneticists call a "jumping gene"—a segment of DNA capable of copying itself and inserting into new locations within the genome. When this particular jumping gene lands in the ATM gene, it disrupts the cell's ability to repair damaged DNA, a malfunction that significantly elevates cancer risk. The mutation likely arose around 300 years ago, during the initial waves of French colonization in the 1600s, and has persisted through roughly ten to eleven generations of descendants.
Quebec's French-Canadian population offers an unusual window into how rare genetic variants can become concentrated over time. The settlers who arrived from France were relatively few in number, and as their descendants multiplied across generations, certain genetic mutations that were uncommon in the broader European population became far more prevalent in this isolated group—a phenomenon geneticists call the founder effect. William Foulkes, a Distinguished James McGill Professor in the university's departments of medicine, oncology, and human genetics, explained that this particular population history creates ideal conditions for studying inherited disease, since a small number of ancestral mutations can account for a substantial share of hereditary cases.
The numbers tell a striking story. Among French-Canadians in Quebec diagnosed with pancreatic cancer, the mutation appears in roughly 2 percent of cases. In the general unaffected population, it shows up in only 0.2 percent—a tenfold difference. The researchers also found the variant overrepresented in French-Canadian women with breast cancer, suggesting it elevates risk for that malignancy as well. Their analysis drew on patient samples from the Quebec Pancreas Cancer Study and population data from CARTaGENE, a large genetic biobank.
For decades, this mutation remained invisible to standard genetic testing. The older sequencing technologies simply could not reliably detect this particular type of DNA alteration. That changed with the arrival of newer sequencing methods, which can now identify the variant with precision. George Zogopoulos, a McGill professor of surgery and oncology and surgeon at the McGill University Health Centre, noted that the tenfold enrichment in pancreatic cancer cases represents a significant difference in relative risk—one that could translate into practical clinical benefit. "This means it may be possible to identify people at higher risk by testing for this variant," he said.
Yifan Wang, the study's first author, who conducted the research as a resident and doctoral student at McGill, sees a path forward in targeted genetic screening. Rather than relying on broad panels that test for hundreds of variants, clinicians could develop focused panels that look for a small number of key cancer-related founder mutations specific to particular populations. Such an approach could help identify at-risk individuals earlier, when interventions might be most effective. Wang also raised an important point for those who underwent genetic testing five to ten years ago: they may now benefit from re-evaluation through genetic counseling, given that the technology has advanced significantly since their initial screening.
Notable Quotes
This population history creates unique opportunities to study inherited disease, since a small number of founder mutations account for a significant fraction of all hereditary cases.— William Foulkes, Distinguished James McGill Professor
Although it is rare in the general population, it is strongly enriched in pancreatic cancer cases. That's a significant difference in relative risk.— George Zogopoulos, McGill Professor of Surgery and Oncology
The Hearth Conversation Another angle on the story
Why does this mutation matter more in Quebec than anywhere else?
It's about population history. A small group of French settlers arrived in the 1600s, and this mutation was probably present in one or a few of them. Over 300 years and ten generations, it spread through their descendants. In the broader world population, it's vanishingly rare. But here, it's concentrated.
So the mutation itself isn't new—it's just old and local?
Exactly. It arose around 300 years ago, probably during early settlement. It's not that French-Canadians are genetically different in some fundamental way. It's that this one variant got trapped in a smaller population and amplified over time.
How much does it actually increase someone's cancer risk?
If you carry it, you're about ten times more likely to develop pancreatic cancer than someone without it. It also seems to raise breast cancer risk. But it's still not a certainty—it's a significant elevation, not a guarantee.
Why couldn't doctors find this before?
The older genetic tests just weren't sensitive enough to detect this particular type of DNA change. It's a jumping gene insertion—a specific kind of mutation. The new sequencing technology can catch it now.
What happens next for someone who finds out they carry it?
That's the real opportunity. If you know you have it, you can be monitored more closely, screened earlier, and potentially catch cancer at a more treatable stage. People who were tested years ago might want to get retested with the newer methods.